Digestive system neuroendocrine neoplasm

This early-phase trial tests whether adding triapine to standard radioactive therapy (lutetium Lu 177 dotatate) is safe and effective for people with advanced neuroendocrine tumors of the digestive system. About 31 participants whose tumors have worsened after prior treatment wil…

This Phase II trial tests whether combining lenvatinib and everolimus can shrink or slow advanced carcinoid tumors that cannot be removed by surgery. The study enrolls 36 adults with confirmed unresectable carcinoid tumors. Both drugs are taken orally and work by blocking enzymes…

This study tests the drug tarlatamab in people with advanced tumors that have a protein called DLL3. The goal is to see if the drug can shrink or control these tumors. About 29 adults with stage IV cancer will receive tarlatamab, and researchers will track how well it works and a…

This study tested a drug called pazopanib in 171 people with carcinoid tumors that were growing or spreading. The goal was to see if pazopanib could slow tumor growth better than a placebo. Participants were randomly assigned to receive either pazopanib or a placebo, and research…

This study tests whether adding a vaccine called SurVaxM to the chemotherapy drug temozolomide can help control advanced neuroendocrine tumors that are growing. About 60 adults with these rare cancers will receive either the combination or chemo alone. The goal is to see if the v…

This early-phase study is testing whether giving a radioactive drug called Lutathera both before and after surgery is safe for people with advanced neuroendocrine tumors that have spread to the liver or lymph nodes. The trial will enroll 10 adults whose tumors are considered remo…

This study tests whether the drug cabozantinib can slow the growth of advanced neuroendocrine tumors (including carcinoid tumors) compared to a placebo. About 298 adults whose cancer worsened after prior treatment will receive either cabozantinib or a placebo pill. The main goal …

This phase 3 trial compares a new form of octreotide (CAM2029) given as a shot every 2 weeks to standard monthly injections in 332 people with advanced neuroendocrine tumors of the gut or pancreas. The main goal is to see if the new drug delays tumor growth better than current tr…

This phase 2 trial tests a combination of two immunotherapy drugs, domvanalimab and zimberelimab, in people with five types of advanced rare cancers (peritoneal mesothelioma, gestational trophoblastic tumor, anaplastic thyroid carcinoma, neuroendocrine tumors, and thymic carcinom…

This Phase 2 trial tests an oral drug called ESK981 in people with advanced pancreatic cancer, neuroendocrine tumors, or neuroendocrine prostate cancer. The goal is to see if the drug can keep the cancer from growing for at least 4 months. Participants take the drug for 5 days, t…

This early-phase study tests a new drug called E7386 in about 70 people with advanced solid tumors, including colorectal cancer. The main goal is to check safety and find the right dose. Participants have tumors that no longer respond to standard treatments.

This study is testing a radioactive drug called Lutathera in teenagers aged 12 to 17 who have rare tumors of the digestive system or adrenal glands. The goal is to see if the drug is safe and how much radiation reaches organs. Eleven teens are taking part, and researchers are wat…

This study tested whether adding Lutathera to standard octreotide treatment can delay tumor growth in people with advanced neuroendocrine tumors of the stomach, intestines, or pancreas. The trial involved 226 patients with fast-growing tumors (grades 2 and 3) who had not received…

This phase 2 trial tests the drug abemaciclib (Verzenio) in 20 patients with advanced gastroenteropancreatic neuroendocrine tumors that have spread, are not responding to treatment, and cannot be surgically removed. The drug works by blocking enzymes that help cancer cells grow. …

This phase II trial is testing an oral drug called CVM-1118 in 34 people with advanced neuroendocrine tumors that have not responded to standard treatments. The drug aims to slow tumor growth and improve disease control. Participants take the pill twice daily, with a possible dos…

This Phase 3 trial tests a radioactive drug called 177Lu-Edotreotide against standard chemotherapy for people with aggressive neuroendocrine tumors of the gut or pancreas. The drug targets tumor cells and delivers radiation directly. About 259 participants will be followed to see…

This study follows over 2,500 people with neuroendocrine tumors (NETs) to understand their symptoms and how treatments are chosen. Participants fill out surveys about quality of life and care experiences over 18 months. Researchers will link this to medical records to find which …